|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.60 CHF | -0.14% |
|
-0.24% | +15.51% |
| 01:46am | Novartis' Pluvicto Gets US FDA Nod for Metastatic Prostate Cancer Treatment | MT |
| 07-31 | Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto | DJ |
Evolution of the Average Target: Novartis AG
Evolution of the Target Price: Novartis AG
Changes in Analyst Recommendations: Novartis AG
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | -1.58% | |||||
| +11.15% | |||||
| +5.73% | |||||
| +7.75% | |||||
| +2.92% | |||||
| +24.88% | |||||
| +3.49% | |||||
| -7.3% | |||||
| +20.69% | |||||
| +14.95% | |||||
| Average | +8.27% | |||||
| Weighted average by Cap. | +8.13% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| AlphaValue/Baader Europe | |
| Berenberg Bank | |
| BERENBERG | Kerry Holford |
| JEFFERIES | Michael Leuchten |
| DZ BANK | Elmar Kraus |
| alphavalue | Abhishek Raval |
| UBS | Matthew Weston |
| JPMORGAN | Richard Vosser |
| BERNSTEIN RESEARCH | Justin Smith |
| GOLDMAN SACHS | James Quigley |
| BARCLAYS | James Gordon |
| Citigroup | |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| Morningstar | |
| Morgan Stanley | |
| Intron Health | |
| Bank Vontobel AG | |
| BNP Paribas Exane | |
| DA Davidson | |
| HSBC | |
| Octavian AG | |
| Jefferies & Co. | |
| Deutsche Bank Securities | |
| Baader Bank | |
| BMO Capital | |
| Kepler Capital Markets | |
| Societe Generale | |
| Redburn | |
| Stifel Nicolaus | |
| BNP Paribas | |
| Barrington Research | |
| International Strategy & Investment Group | |
| Credit Suisse | |
| ODDO BHF | |
| Zacks Equity Research | |
| Bank of America Securities/Merrill Lynch | |
| Kepler Cheuvreux | |
| Wolfe Research | |
| AltaCorp Capital | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Exane BNP Paribas | |
| Bryan, Garnier & Co. | |
| Moody's Investors Service | |
| Dundee | |
| Exane BNP | |
| Bernstein | |
| Argus | |
| Cowen | |
| BRYAN GARNIER | Eric Le Berrigaud |
| LIBERUM CAPITAL | Graham Doyle |
| BANK OF AMERICA (BOFA) | Graham Parry |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
- Consensus Novartis AG
Select your edition
All financial news and data tailored to specific country editions
